Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
Description
CONCLUSIONS: In one in three published clinical trials on covid-19 drugs, the quality of reporting of adverse events was low or very low. Differences were found in the number of serious adverse events reported in journal articles versus clinical
